Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
As of 03:42PM EDT. Market open.
| Previous Close | 105.84 |
| Open | 105.12 |
| Bid | 105.32 x 800 |
| Ask | 105.33 x 900 |
| Day's Range | 105.11 - 106.55 |
| 52 Week Range | 85.67 - 119.65 |
| Volume | |
| Avg. Volume | 6,912,519 |
| Market Cap | 267.493B |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | 86.41 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.92 (2.76%) |
| Ex-Dividend Date | Sept 14, 2023 |
| 1y Target Est | N/A |
- Zacks
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
- Zacks
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
- Zacks
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
© 2023 Yahoo. All rights reserved.
